Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Castle Biosciences

31/07/2026 07:10

Castle Biosciences Inc CSTL.OQ reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 15 cents.  The mean expectation of nine analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -53 cents to -30 cents per share.
Revenue rose 20.1% to $103.55 million from a year ago; analysts expected $86.24 million. 
Castle Biosciences Inc's reported EPS for the quarter was a loss of 7 cents​.
The company reported a quarterly loss of $2.06 million.
Castle Biosciences Inc shares had risen by 12.3% this quarter and lost 31.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 32.3% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is  "buy."
Wall Street's median 12-month price target for Castle Biosciences Inc is $40.00, about 33% above its last closing price of $26.79
This summary was machine generated from LSEG data July 31 at 06:10 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.41
-0.07
Beat
Mar. 31 2026 
-0.49
-0.49
Met
Dec. 31 2025 
-0.29
-0.08
Beat
Sep. 30 2025 
-0.52
-0.02
Beat